<DOC>
	<DOCNO>NCT00702949</DOCNO>
	<brief_summary>RATIONALE : Pregabalin may help relieve hot flash woman history breast cancer history wish take estrogen therapy fear increase risk breast cancer . It yet know dose pregabalin may effective treat hot flash . PURPOSE : This randomized phase III trial determine efficacy two dos pregabalin , comparison placebo , prevention hot flash .</brief_summary>
	<brief_title>Pregabalin Treating Women With Hot Flashes</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy 150 mg pregabalin versus placebo hot flash score woman history breast cancer woman wish take estrogen therapy fear increase risk breast cancer . - To evaluate side effect profile different dos pregabalin patient . - To evaluate effect 150 mg pregabalin versus placebo secondary outcome interference activity hot flash patient . - To evaluate efficacy side effect profile 75 mg pregabalin versus placebo patient . OUTLINE : Patients stratify accord age ( 18-49 year vs ≥ 50 year ) ; selective estrogen-receptor modulator ( i.e. , tamoxifen raloxifene ) aromatase inhibitor use ( yes v ) ; duration hot flash ( &lt; 9 month vs ≥ 9 month ) ; frequency hot flash per 24-hour period ( 4-9 v ≥ 10 ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive 75 mg oral pregabalin twice daily 6 week . - Arm II : Patients receive 150 mg oral pregabalin twice daily 6 week . - Arm III : Patients receive oral placebo twice daily 6 week . Treatment arm continue absence unacceptable toxicity . Patients complete Hot Flash Diaries baseline daily treatment Symptom Experience Diary baseline weekly treatment . Patients also complete Profile Mood States Hot Flash Related Daily Interference Scale questionnaires baseline completion study treatment .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meeting 1 follow criterion : History breast cancer ( currently without malignant disease ) No history breast cancer , patient wish avoid estrogen due perceive increased risk breast cancer Bothersome hot flash ( define occurrence ≥ 28 time per week sufficient severity make patient desire therapeutic intervention ) Presence hot flash ≥ 1 month prior study entry PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Life expectancy ≥ 6 month Able complete questionnaire ( ) assistance Women childbearing potential eligible ( per judgment attend clinician ) Serum creatinine ≤ 1.5 time upper limit normal PRIOR CONCURRENT THERAPY : No prior gabapentin pregabalin More 4 week since prior concurrent antineoplastic chemotherapy , androgen , estrogen , progestational agent Vaginal estrogen allow use past month plan discontinue Concurrent adjuvant target therapy ( i.e. , lapatinib , trastuzumab [ Herceptin® ] ) allow patient evidence disease Concurrent tamoxifen , raloxifene , aromatase inhibitor constant dose least 4 week allow provided medication stop study period No concurrent plan use agent hot flash except follow : Stable dose vitamin E allow long agent start &gt; 30 day prior study initiation continue throughout study period Soy allow , plan continue dose study period Stable dose antidepressant allow long start &gt; 30 day prior study initiation continue stable dose throughout study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>hot flash</keyword>
</DOC>